Axsome Therapeutics (AXSM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.99
- Estimate
- -$0.84
- Surprise
- -17.2%
- Revenue (period 2026-06-30)
- $218.4M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
Axsome Therapeutics (AXSM) reported a wider loss than forecast — adjusted EPS of -$0.99 against the -$0.84 estimate (a 17.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AXSM Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -17.2% surprise compares with a -13.4% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Quality below floor (3.7 < 4.0)
- Momentum score 1.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $195.14
- Price target
- $256.86
- Stop
- $183.38
- Upside to target
- +31.6%
- Reward-to-risk
- 3.6:1
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
AXSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.13B
- P/E (fwd)
- 38.4
- 52-week range
- $115.31–$260.19
- Off 52-week high
- 25.0%
- RSI (14)
- 40
- Volume vs avg
- 0.30×
- Score today
- 5.2/10